Bimagrumab Plus Semaglutide for Obesity Management: Analysis of a Phase 2 Randomized Controlled Trial Demonstrating Enhanced Weight Reduction with Lean Mass Preservation

A phase 2 randomized controlled trial demonstrated that the combination of bimagrumab and semaglutide achieved superior weight reduction compared with semaglutide monotherapy while preserving lean muscle mass. The combination therapy resulted in a least squares mean weight loss of 17.8 kg versus 14.2 kg with semaglutide alone at 48 weeks.